We lead next-generation drug delivery platforms based on advanced technologies and devices.
Solid‑Dose Platform Technology
Based on its accumulated formulation development experience, Daewoong Pharmaceutical has established proven formulation technologies across a wide range of therapeutic areas.
Building on this solid foundation, the company focuses on advanced formulation technology platforms, including immediate-release and controlled-release formulations (both single-entity and fixed-dose combinations), release control technologies, solubility enhancement, and salt modification.
Leveraging these capabilities, Daewoong leads the development of new drugs and incrementally modified drugs (IMDs), while improving patient convenience and optimizing therapeutic efficacy.
Focus areas
Cardiovascular Diseases
Gastrointestinal Disorders
Diabetes / Obesity
Psychiatric Disorders
Autoimmune Diseases
Oncology
Aging-Related Conditions
Cardiovascular Diseases
Gastrointestinal Disorders
Diabetes / Obesity
Psychiatric Disorders
Autoimmune Diseases
Oncology
Aging-Related Conditions
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
Tablets in Capsule
Tablet-in-Capsule (TiC) technology is an advanced combination formulation that delivers tablet-form drugs within a capsule.
Based on tablet miniaturization and TiC technology, Daewoong Pharmaceutical is actively pursuing global collaborations to develop multi-indication combination products and expand personalized combination therapy platforms.
Core Competency 02
OROS (Osmotic-controlled Release Oral Delivery System)
OROS technology is an advanced controlled-release formulation that utilizes osmotic pressure to minimize fluctuations in plasma drug concentration and improve the consistency of therapeutic effects.
To support the development of long-acting incrementally modified drugs (IMDs), Daewoong Pharmaceutical is expanding osmotic-based formulation research across therapeutic areas including central nervous system (CNS), neuropsychiatric disorders, and cardiovascular diseases, while strengthening internal capabilities and global collaborations to build high-value drug delivery systems.
Core Competency 03
Multi Unit Particle System (MUPS)
MUPS technology is a controlled-release system in which drug-loaded pellets or granules are compressed into tablets or filled into capsules, enabling stable and uniform drug delivery.
Leveraging MUPS technology, Daewoong is advancing the development of personalized release formulations, commercialization of multi-i ndication combination products, and expansion of global partnerships. This technology is strategically integrated with TiC and tablet miniaturization to enhance patient-centric treatment solutions.
Core Competency 04
Active Coating
Active Coating is a functional coating technology that directly incorporates active pharmaceutical ingredients (APIs) into the coating layer, enabling precise control of drug release timing and patterns.
This technology allows precise dosing of low-dose active pharmaceutical ingredients (APIs) and supports tablet size reduction, improving patient convenience. Daewoong Pharmaceutical plans to expand this platform across multiple therapeutic areas through diverse combinations of ingredients and dosages, while advancing it into a next-generation combination formulation platform for global markets.
Core Competency 05
Additional Technologies
- Combination formulation technologies
- DOLTAB™ (Double-Layered-Tablet)
- MORATAT™ (Modified Release and Absorption by Tablet in Tablet)
- ORASIMS™ (Optimized Release and Absorption by Simple Monolithic System)
- Sustained-release technologies
- MuTAS™ (Multi-Target controlled release System)
- McReS™ (Monolithic controlled-Release System)
- GASRiCs™ (Gastric Swelling & Retention in Controlled-release system)
- Solubilization technologies
- SOTBAI™ (Solubilization Technology for Bioavailability Improvement)
- NATOM™ (Nanotechnology of Optimal wet-Milling)